Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 537.70B |
| Revenue (ttm) | 42.36B |
| Net Income (ttm) | 10.97B |
| Shares Out | n/a |
| EPS (ttm) | 12.16 |
| PE Ratio | 48.99 |
| Forward PE | 26.74 |
| Dividend | 4.98 (0.84%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | n/a |
| Average Volume | 1 |
| Open | n/a |
| Previous Close | 590.00 |
| Day's Range | n/a |
| 52-Week Range | 538.92 - 805.00 |
| Beta | 0.33 |
| RSI | 51.33 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Thousands in England unable to access weight loss jabs via GP, figures reveal
Doctors say NHS rollout not fit for purpose with fewer than half of commissioning bodies prescribing Mounjaro Thousands of patients in England are unable to access weight loss jabs via their GP, figur...
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...
Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development
Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Disease...
Alexandria Real Estate Equities, Inc. Named One of the World's Most Trustworthy Companies by Newsweek for the Second Consecutive Year
PASADENA, Calif. , Sept. 4, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborativ...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be present...
Where Will Eli Lilly Be in 3 Years?
The weight-loss drug opportunity could approach $100 billion by the end of the decade.
Eli Lilly's Stock Fall Is An Opportunity
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Eli Lilly Wins Fresh Bullish Call From BMO
Eli Lilly Wins Fresh Bullish Call From BMO
Defiance ETFs launches 2X short ETF on Eli Lilly
This House of Representative Just Bought Up To $245K In Eli Lilly Stock
An official report on September 2, 2025 reveals Representative David Taylor's recent purchase of Eli Lilly (NYSE: LLY) stock, valued between $28,014 and $245,000. The transaction took place on August...
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLY...
Jim Cramer Says This “Ridiculously Cheap” Healthcare Stock is a Buy
Healthcare investing has felt like walking through quicksand this year. One moment, the sector looks ready to spring forward on breakthrough drugs and aging demographics, the next, it is yanked back b...
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
Novo Nordisk's Wegovy cut cardiovascular risks ... Full story available on Benzinga.com
Novo Nordisk (NVO) Jumps as Wegovy Beats Eli Lilly in Cardiovascular Outcomes
Novo Nordisk (NVO) Jumps as Wegovy Beats Eli Lilly in Cardiovascular Outcomes
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Notable healthcare headlines for the week: UnitedHealth, J&J and Eli Lilly in focus
Explore the latest healthcare market shifts: gains, losses, policy impacts, and major acquisitions, including Eli Lilly's obesity drug progress.
Novo's Wegovy beats Lilly’s Zepbound in real-world study for heart diseases
Novo Nordisk (NVO) stock in focus as its obesity drug Wegovy outperforms Eli Lilly's (LLY) rival Zepbound in reducing serious heart issues by over 50%. Read more here.
Notable analyst calls this week: AMD, Eli Lilly and Constellation Brands among top picks
Discover key stock upgrades and downgrades this week, including AMD's AI potential, AMD vs Nvidia insights, and market movements.
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. Markets concluded August on a mixed note. The S&P 500 dipped 0.6% on ...
Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat.
Eli Lilly's retatrutide is still in clinical trials. But gym bros are already using a version of the weight-loss drug, amid a growing DIY culture in fitness circles.
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly (NYSE: LLY) is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tec...
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI ...
Eli Lilly joins forces with China tech giant to expand obesity drug market
Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-l...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.